

Spontaneous or photo-induced resolution of papular elastolytic giant cell granuloma? A case report with considerations on its etiopathogenesis and clinical approach

Andrea Marani,¹ Davide Bertolla,² Alessia Caligiure,² Anna Rita Lombardi,³ Andrea Conti¹

¹Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini; ²Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara; ³Anatomical Pathology Unit, Department of Oncohematology, Infermi Hospital, AUSL Romagna, Rimini, Italy

Abstract

Papular elastolytic giant cell granuloma (PEGCG) is a rare subtype of elastolytic giant cell granuloma (EGCG), typically presenting as asymptomatic papules in non-photo-exposed areas and lacking annular or photo-distributed lesions. Histologically, it overlaps with other EGCG variants, showing features like elastolysis, elastophagocytosis, and multinucleated giant cell infiltrates. The etiopathogenesis remains unclear, particularly the role of ultraviolet (UV) radiation, and its clinical management is not well defined. We report a case of PEGCG that, after a one-year history, achieved complete clinical remission following two and a half months of sun exposure during the summer (heliotherapy). This case offers insights into its etiopathogenesis and clinical management, supported by a review of the existing literature.

Key words: elastolysis; actinic granuloma; annular granuloma; giant cell granuloma; sun exposure.

Correspondence: Andrea Conti, Dermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, AUSL Romagna, viale Settembrini 2, 47924 Rimini, Italy. Tel.: +39 3472380244. Fax: +39 0541705002. E-mail: a.conti.dermo@gmail.com

Introduction

Papular elastolytic giant cell granuloma (PEGCG) is an uncommon clinical variant of annular elastolytic giant cell granuloma (AEGCG), a rare granulomatous skin disorder. AEGCG is characterized by annular, centrifugally expanding lesions primarily on sun-exposed areas, with histological features including elastolysis, elastophagocytosis, and multinucleated giant cell infiltration.^{1,2} Recently, the term “elastolytic giant cell granuloma” (EGCG) has been adopted to encompass a broader spectrum of clinical subtypes, replacing earlier terms such as “AEGCG” and “actinic granuloma” (AG), the latter introduced by O’Brien in 1975.^{1,2} This shift reflects reports indicating that EGCG lesions are not always annular or limited to photo-exposed areas, supporting the concept of a family of EGCG subtypes rather than defining AEGCG as a singular entity with rare variants.³

PEGCG, as a papular clinical subtype of EGCG, typically lacks annular or photo-distributed lesions. Instead, it presents as multiple, asymptomatic, erythematous to skin-colored, non-scaly, indurated papules on the trunk and extremities. Its recognition challenges traditional assumptions about EGCG pathogenesis and nosology. While elastic fiber degeneration remains central to EGCG, the role of ultraviolet (UV) radiation has become increasingly debated.³ Recent reports describe EGCG in non-photo-distributed areas, highlight the papular PEGCG subtype, and even

document paradoxical remission of PEGCG with narrow-band (NB)-UVB irradiation.^{4,5} Here, we present a case of PEGCG that resolved following prolonged summer sun exposure, providing insights into the pathogenesis, nosology, and clinical management of PEGCG, supported by a review of the existing literature.

Case Report

A 79-year-old woman presented with a one-year history of asymptomatic macules and papules distributed across her trunk and extremities. The lesions initially appeared flat and gradually became palpable. During the consultation, she expressed significant concern about her condition.

Her medical history included osteoporosis, diverticulosis, and hereditary thrombophilia. She had been under angiologic follow-up and on anticoagulant therapy for thrombophilia but was not taking medication for osteoporosis or diverticulosis. She reported no recent introduction of new drugs but noted mild asthenia over the past year, without other systemic symptoms.

On examination, the patient had pink to red, firm, smooth macules and papules on her back, thighs, and arms (Figure 1 A,B). The lesions were confluent but did not form annular patterns, with the back being the most affected area (Figure 1C). The body surface area involved was approximately 20%. Differential diagnoses

included EGCG, disseminated granuloma annulare (GA), lichen myxedematosus, and clinically atypical sarcoidosis.

A skin biopsy revealed orthokeratotic epidermis, chronic granulomatous inflammation with histiocytes, multinucleated Langhans-type giant cells, and focal mucin deposits (Figure 2 A,B). Higher magnification showed multinucleated giant cells phagocytosing broken elastic fibers (elastophagocytosis) with associated elastolysis in the dermal interstitium (Figure 2C). There was no evidence of necrobiosis or palisading granulomas. Superficial and deep perivascular lymphocytic inflammation was observed. Fungal elements and alcohol-acid-resistant bacilli were absent. The histological finding was compatible with EGCG, and, considering the clinical presentation, a diagnosis of PEGCG was made. Based on the literature, investigations of the patient included chest radiography, abdominal ultrasound, ophthalmological evaluation, and routine blood tests to rule out underlying systemic pathology and consider systemic treatment options, such as hydroxychloroquine.^{2,6} The first visit occurred in July 2024. The patient came to follow up at the end of September 2024 in complete clinical remission. Instrumental and laboratory findings were normal, and her asthenia had resolved. Physical examination revealed normal, lesion-free but markedly tanned skin (Figures 3), as demonstrated by iconographic comparison with July 2024 (Figures 2 and 3). The patient reported significant sun exposure during the summer without sunscreen and recognized much greater sun exposure than the previous summer. The patient returned for follow-up at the end of September 2024 and was in complete clinical remission. The resolution of asthenia was attributed to the alleviation of psychological distress associated with her condition.

Discussion

The first description of PEGCG was reported in 1989 by Kato *et al.*, detailing a 55-year-old patient with multiple annular lesions on the trunk and numerous papules on the upper back and forearms. The histological examination of a skin lesion confirmed EGCG, marking the initial diagnosis of its papular subtype.⁷ Since then, other atypical papular variants have been identified. In 1999, Morita *et al.* described a generalized papular variant without annular lesions, while Misago *et al.* reported a case with both papular and reticular lesions.^{8,9} In 2009, Rongioletti *et al.* documented a



Figure 1. Clinical picture at first evaluation. Pink or small red, firm to touch, smooth macules and papules diffuse to the back (A), thighs (B), and arms. Higher magnification detail of the lesions, purely papular, without annular structures (C).

case resembling Morita's, though with notable histopathological differences.¹⁰ More recently, larger case series of PEGCG have emerged, although it remains rare, with limited literature.^{2,6,11} We owe to these recent scientific studies the first attempt to classify the EGCG family into clinically distinct variants: annular, papular, and mixed,⁶ or annular, papular, giant, generalized, and mixed.²




Figure 2. Histopathological picture in hematoxylin and eosin at 10x (A), 20x (B), and 40x (C) magnification. At 10x and 20x magnification (A, B) orthokeratotic epidermis and chronic granulomatous inflammation with histiocytes and multinucleated Langhans-type giant cells phagocytosing (elastophagocytosis) broken elastic fibers (elastolysis) are observed. Elastophagocytosis and elastolysis are best seen at 40x; elastophagocytosis is highlighted by arrows (C). Mucin deposits are evidenced by histochemical staining with Alcian blue (D).




Figure 3. Clinical picture at second evaluation. The areas previously affected by PEGCG at both low (A, B) and high magnification (C) were free of lesions. Only clearly tanned skin is observed (A-C).

An important contribution by Limas *et al.* established histological criteria for EGCG diagnosis, distinguishing it from GA by the presence of predominant elastolysis and elastophagocytosis without necrobiosis or palisading granulomas.¹² The key histological features of EGCG include: i) absence of mucin and necrobiosis; ii) prominence of multinucleated giant cells, elastolysis, and elastophagocytosis; and iii) absence of palisading granulomas.⁹ These criteria are consistent across EGCG variants, including PEGCG, as no definitive histological differences exist among them. However, histological overlap with GA has been reported. For instance, de Oliveira *et al.* described a case of EGCG with features of granulomatous inflammation, elastophagocytosis, and elastolysis, alongside necrobiosis and palisading granulomas.¹³ Similarly, our case demonstrated focal mucin deposits, a finding uncommon in EGCG but insufficient to exclude a diagnosis of PEGCG given the overall clinical and histopathological presentation. Another possible differential diagnosis could have been type III mid-dermal elastolysis. It clinically presents with persistent reticulated erythema and skin wrinkling localized to the trunk. Its clinical presentation may resemble our case, although coalescence of papules is the characteristic clinical finding of PEGCG. In addition, histologically, mid-dermal elastolysis characteristically presents with loss of elastic fibers in the mid-dermis and only occasionally multinucleated giant cells and elastophagocytosis.¹⁴

PEGCG has been linked to various clinical conditions, including hyperlipidemia, sideropenic anemia, angina, shingles,⁶ and monoclonal gammopathy.¹⁰ Notably, there is only one reported case of PEGCG presenting as a paraneoplastic manifestation of relapsed follicular lymphoma, which resolved following allogeneic hematopoietic stem cell transplantation.¹⁵ In our case, the patient's medical history does not appear to be directly related to the development of PEGCG, and thorough investigations ruled out other underlying conditions.

The treatment of PEGCG remains unstandardized, with reported therapeutic attempts including topical steroids,⁶ topical tacrolimus,¹⁰ hydroxychloroquine, and griseofulvin.¹⁶ Medications effectively used for AEGCG, such as methotrexate, cyclosporine, and fumaric acid, have not yet been reported for PEGCG. Interestingly, at least five cases of spontaneous regression of PEGCG have been documented, a phenomenon not observed in AEGCG, suggesting that the papular subtype may have a unique tendency for resolution without treatment.^{1,6,9,17,18}

Notably, Takata *et al.* reported a case of PEGCG successfully treated with NB-UVB phototherapy.⁵ This case is particularly intriguing given that UV radiation is considered a potential trigger or exacerbating factor for EGCG. The authors attribute the therapeutic effects to the specific mode of irradiation: while chronic exposure to low doses and broad UV wavelengths may induce granulomatous reactions by altering connective tissue antigenicity, acute exposure to high doses and selective wavelengths, such as NB-UVB, may have therapeutic benefits.⁵ NB-UVB is particularly effective because it targets the upper dermis, where granulomatous infiltration occurs.⁵ Our case closely resembles those described above, as our patient experienced non-pharmacological resolution of PEGCG. However, it remains uncertain whether this resolution was truly spontaneous or photo-induced. The disease's persistence over one year, followed by remission during two and a half months of summer sun exposure, suggests a potential causal role for heliotherapy. This represents the second reported case, after Takata *et al.*, where UV radiation – a presumed causative factor – appears to have therapeutic or potentially therapeutic effects.

Uniquely, in our case remission was associated with natural

sun exposure which, although occurring over a period of more than two and a half months, may still be considered an “acute” exposure and differs from NB-UVB phototherapy in terms of radiation type (e.g., about 99% of the UV that reaches the earth's surface is UVA).

The remission linked to intense or prolonged sun exposure raises questions about the pathogenesis and classification of a disease historically associated with actinic damage.^{3,16}

Early pathogenic theories, such as those by O'Brien, posited that EGCG's clinical variants depend on the degree of immune response and the type of elastic tissue involved.¹⁹ Annular lesions were thought to result from complete, centrifugal elastophagocytosis of actinically damaged fibers, while generalized papular lesions were linked to a systemic immune response to mildly damaged or intact elastic tissue.⁹ Although elastic fiber degeneration remains central to EGCG, the role of UV radiation in its pathogenesis – particularly in PEGCG – appears less definitive.

For instance, Caldas *et al.* described PEGCG in an obese, diabetic patient with papules localized to adipose areas.¹⁶ They proposed that the adipose tissue's cytokine profile might trigger a granulomatous reaction against nearby glycosylated, damaged elastic fibers. A similar mechanism may explain EGCG cases associated with systemic conditions like hematologic malignancies, underscoring the need for further investigation into their pathogenesis.^{15,16} Although further validation is needed, we support the pathogenic model proposed by Caldas *et al.*, for which our report provides additional evidence. The pathogenesis of PEGCG may differ from that of AEGCG, even though both are driven by damage to elastic fibers. AEGCG could represent a granulomatous, cell-mediated inflammatory response to elastic fibers severely damaged by sunlight, which explains its predilection for photo-exposed areas. In contrast, PEGCG may result from a similar inflammatory response to mildly damaged elastic fibers, with damage potentially triggered by factors other than sunlight, such as diabetes, malignancies, or unknown processes.

Elastic fibers can be compromised not only by sun exposure but also by endogenous and exogenous factors (e.g., glycation or calcification), collectively contributing to the so-called “aging” of elastic fibers, even if photo-exposed areas consistently show greater elastic fiber damage compared to non-exposed regions.²⁰ This hypothesis aligns with early models by O'Brien and other authors and more recent studies.

A distinct pathogenesis could explain the differing clinical presentations and disease courses, with PEGCG demonstrating potential for spontaneous remission if the “non-solar” stimulus is removed. This may also clarify why, in our patient, PEGCG was not induced but instead resolved during sun exposure, suggesting that the pathogenesis of PEGCG may not be as tightly linked to actinic damage as traditionally thought.

Conclusions

In conclusion, our case report offers three key insights when compared with other PEGCG cases in the literature. First, a “wait-and-watch” approach, where the patient is informed but no immediate treatment is given, appears justified for asymptomatic PEGCG, as spontaneous remission has been reported in several cases.^{1,6,9,17,18} Ongoing monitoring with laboratory and instrumental investigations is recommended to rule out underlying causes and anticipate potential therapy. Second, phototherapy and heliotherapy may represent viable treatment options; however, they should

be used with caution, given the incomplete understanding of PEGCG pathogenesis and the moderate to strong correlation with sun exposure reported by Chen *et al.* in some cases.⁶ In contrast, photoprotection is advised for AEGCG. Finally, a more precise nosography and classification of PEGCG within the spectrum of EGCG, and in relation to AEGCG and GA, is certainly needed to clarify its etiopathogenesis and improve its clinical approach.

References

- O'Brien JP. Actinic granuloma. An annular connective tissue disorder affecting sun- and heat-damaged (elastotic) skin. *Arch Dermatol* 1975;111:460-6.
- Qian YT, Liu JW, Liu W, et al. A Retrospective Study of 105 Patients with Elastolytic Giant Cell Granuloma and a Proposal for a New Clinical Classification. *Acta Derm Venereol* 2022;102:adv00684.
- Gutiérrez-González E, Pereiro M Jr, Toribio J. Elastolytic Actinic Giant Cell Granuloma. *Dermatol Clin* 2015;33:331-41.
- Parikh SA, Que SKT, Holmes WD, et al. Infiltrated papules on the trunk and headaches: A case of actinic granuloma and a review of the literature. *Int J Womens Dermatol* 2015;1:131-5.
- Takata T, Ikeda M, Kodama H, Ohkuma S. Regression of papular elastolytic giant cell granuloma using narrow-band UVB irradiation. *Dermatology* 2006;212:77-9.
- Chen WT, Hsiao PF, Wu YH. Spectrum and clinical variants of giant cell elastolytic granuloma. *Int J Dermatol* 2017;56:738-45.
- Kato H, Uyeki Y, Yaoita H. Papular lesions associated with annular elastolytic giant cell granuloma. *J Am Acad Dermatol* 1989;21:398-400.
- Morita K, Okamoto H, Miyachi Y. Papular elastolytic giant cell granuloma: a clinical variant of annular elastolytic giant cell granuloma or generalized granuloma annulare? *Eur J Dermatol* 1999;9:647-9.
- Misago N, Ohtsuka Y, Ishii K, Narisawa Y. Papular and reticular elastolytic giant cell granuloma: rapid spontaneous regression. *Acta Derm Venereol* 2007;87:89-90.
- Rongioletti F, Baldari M, Burlando M, Parodi A. Papular elastolytic giant cell granuloma: report of a case associated with monoclonal gammopathy and responsive to topical tacrolimus. *Clin Exp Dermatol* 2010;35:145-8.
- Erdogan HK, Arık D, Acer E, et al. Clinicopathological Features of Annular Elastolytic Giant Cell Granuloma Patients. *Turk J Dermatol* 2018;12:85-9.
- Limas C. The spectrum of primary cutaneous elastolytic granulomas and their distinction from granuloma annulare: a clinicopathological analysis. *Histopathology* 2004;44:277-82.
- de Oliveira FL, de Barros Silveira LK, Machado Ade M, Nery JA. Hybrid Clinical and Histopathological Pattern in Annular Lesions: An Overlap between Annular Elastolytic Giant Cell Granuloma and Granuloma Annulare? *Case Rep Dermatol Med* 2012;2012:102915.
- Gambichler T. Mid-dermal elastolysis revisited. *Arch Dermatol Res* 2010;302:85-93.
- Essegian DJ, Issa NT, Nichols A, Milikowski C. Rare presentation of the generalized papular variant of elastolytic giant cell granuloma associated with follicular lymphoma. *JAAD Case Rep* 2021;16:92-5.
- Caldas R, Guimarães MJ, Rodrigues AP, Araújo C. Generalised papular variant of elastolytic giant cell granuloma. *BMJ Case Rep* 2019;12:e231580.
- Hermes B, Haas N, Czarnetzki BM. Anuläres elastolytisches Riesenzellgranulom mit Spontanheilungstendenz [Annular elastolytic giant cell granuloma with a spontaneous healing tendency]. *Hautarzt* 1995;46:490-3.
- Hohenleutner S, Wlotzke U, Landthaler M, Stolz W. Elastolysis of the mid-dermis and annular elastolytic giant cell granuloma: different stages in the clinical spectrum of dermal elastolysis? Case report and review of the literature. *Hautarzt* 1997;48:45-50.
- O'Brien JP. Actinic granuloma: the expanding significance. An analysis of its origin in elastotic ("aging") skin and a definition of necrobiotic (vascular), histiocytic, and sarcoid variants. *Int J Dermatol* 1985;24:473-90.
- Heinz A. Elastic fibers during aging and disease. *Ageing Res Rev* 2021;66:101255.

Received: 27 December 2024; Accepted: 11 April 2025.

Contributions: Andrea Marani, Andrea Conti: research project, data interpretation; Andrea Marani, Davide Bertolla, Alessia Caligiure, Anna Rita Lombardi: data collection; Andrea Marani, Davide Bertolla, Alessia Caligiure, Andrea Conti: manuscript editing; Andrea Marani, Davide Bertolla, Alessia Caligiure: literature review. All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors have no conflict of interest to declare.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient gave her written consent to use her personal data for the publication of this case report and any accompanying images.

Availability of data and materials: not applicable.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).